吉林大学学报(医学版) ›› 2016, Vol. 42 ›› Issue (02): 316-320.doi: 10.13481/j.1671-587x.20160224

• 临床研究 • 上一篇    下一篇

CDA基因单核苷酸多态性对中晚期非小细胞肺癌接受吉西他滨化疗患者预后的影响

糟航1,2, 王旭1, 李薇1   

  1. 1. 吉林大学第一医院肿瘤中心, 吉林长春 130021;
    2. 新疆医科大学研究生学院, 新疆乌鲁木齐 830011
  • 收稿日期:2015-11-06 发布日期:2016-03-31
  • 通讯作者: 李薇,教授,博士研究生导师(Tel:0431-88782180,E-mail:jdyylw@163.com) E-mail:jdyylw@163.com
  • 作者简介:糟航(1990-),女,新疆维吾尔自治区乌鲁木齐市人,在读医学硕士,主要从事临床恶性肿瘤内科学方面的研究。
  • 基金资助:

    卫生与计划生育委员会部属医院临床学科重点项目资助课题(2001133)

Influence of single nucleotide polymorphisms of CDA in prognosis of advanced non-small cell lung cancer patients treated with gemcitabine

ZAO Hang1,2, WANG XU1, LI WEI1   

  1. 1. Tumor Center, First Hospital, Jilin University, Changchun 130021, China;
    2. Graduated School, Xinjiang Medical University, Urumqi 830011, China
  • Received:2015-11-06 Published:2016-03-31

摘要:

目的: 探讨胞苷脱氨酶(CDA)基因单核苷酸多态性(SNPs)对吉西他滨化疗效果的影响,阐明CDA基因SNPs与晚期非小细胞癌(NSCLC)患者临床预后之间的关系。方法: 收集93例经病理确诊后接受吉西他滨化疗的中晚期NSCLC初治患者,应用Sequenom Massarray Genotype系统检测CDA基因79A>C基因型。采用Kaplan-meier方法和Log-rank检验分析CDA基因79A>C SNPs与晚期NSCLC患者无进展生存期(PFS)以及总生存时间(OS)的关系,应用COX风险比例模型分析影响因素对预后的影响。结果: CDA基因79A>C基因多态性与NSCLC患者临床及肿瘤病理特征均未见明显相关性。携带野生型基因型A/A患者经吉西他滨化疗后中位PFS为9.3个月,而携带突变型基因型A/C和C/C患者中位PFS为11个月,二者比较差异无统计学意义(P=0.061)。携带野生型基因型A/A患者中位OS为21.7个月,携带突变型基因型A/C和C/C患者中位OS为22.1个月,二者比较差异无统计学意义(P=0.513)。结论: CDA基因79A>C SNPs对接受吉西他滨化疗的NSCLC患者的PFS有一定延长作用,未发现其SNP与OS有关联。

关键词: 肺肿瘤, 胞苷脱氨酶, 单核苷酸多态性, 化学疗法, 吉西他滨, 预后

Abstract:

Objective: To investigate the influence of single nucleotide polymorphisms(SNP) of cytidine deaminase(CDA) in the curative effect of gemcitabine, and to clarify the correlation of CDA SNP with the clinical prognosis of the advanced non-small cell lung cancer(NSCLC) patients.Methods: CDA 79A>C gene was detected by Sequenom Massarray Genotype System among 93 patients with advanced NSCLC who received chemotherapy of gemcitabine.The associations between CDA 79A>C polymorphisms and progression free survival(PFS) and overall survival(OS) were estimated using Kaplan-meier methods and Log-rank test for univariate analysis, and COX proportional hazards model was used for multivariate analysis.Results: There was no significant correlation between the CDA 79A>C SNPs with the clinical and pathological characteristics of NSCLC patients.The median PFS in the patients with wild genotype A/A was 9.3 months, while the median PFS in the patients with mutant genotype A/C and C/C was 11 months;there was no significant difference between them (P=0.061). The median OS in the patients with wild genotype A/A was 21.7 months, and the median OS of the patients with mutant genotype was 22.1 months;there was no significant difference between them (P=0.513).Conclusion: CDA 79A>C SNPs can prolong the PFS of the NSCLC patients, but it does not affect the OS of the patients.

Key words: lung neoplasms, cytidine deaminase, single nucleotide polymorphisms, chemotherapy, gemcitabine, prognosis

中图分类号: 

  • R734.2